Back to search

Article

Safety and Efficacy of Triple Therapy in Cystic Fibrosis in Pediatric Patients of above 6 Years of Age: A Meta-Analysis of TRIKAFTA (Elexacaftor/Tezacaftor/Ivacaftor)

2025-07-15

Abstract excerpt

<h4>Objective: </h4> To evaluate the safety and efficacy of the triple therapy combination TRIKAFTA (elexacaftor/tezacaftor/ivacaftor) in treating cystic fibrosis (CF) patients with at least one F508del mutation. <h4>Methods: </h4>: A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted using data from PubMed, Web of Science, and Cochrane Library. The protocol was registered on...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7178fc3b-a88c-5788-84fe-1485bee23891
DOI
10.22541/au.175254483.38809429/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety and Efficacy of Triple Therapy in Cystic Fibrosis in Pediatric Patients of above 6 Years of Age: A Meta-Analysis of TRIKAFTA (Elexacaftor/Tezacaftor/Ivacaftor)DOI 10.22541/au.175254483.38809429/v1
Elexacaftor/tezacaftor/ivacaftor-real-world clinical effectiveness and safety. A single-center Portuguese study.Semantic proximity
A retrospective analysis of clinical parameters, safety and tolerability of Elexacaftor/Tezacaftor/Ivacaftor in a cohort of patients aged 6-17 years with cystic fibrosisSemantic proximity
Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3b, Randomized, Placebo-controlled Study.Semantic proximity
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.Semantic proximity
Cystic fibrosis: new challenges and perspectives beyond elexacaftor/tezacaftor/ivacaftor.Semantic proximity
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One F508del Allele.Semantic proximity
Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.Semantic proximity
Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor/tezacaftor/ivacaftor combination therapy.Semantic proximity
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.Semantic proximity
Elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and rare mutations.Semantic proximity
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.Semantic proximity
VX-659–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del AllelesSemantic proximity
Select a neighboring publication to make it the new centre.